Difference between revisions of "Measurements"
From The SpiritWiki
| Line 2: | Line 2: | ||
==Notes== | ==Notes== | ||
Kwonmok et al. provide a list of instruments devoted to measuring [[Connection Outcome]]s.<ref>Kwonmok, Ko, Knight Gemma, James J Rucker, and Anthony J Cleare. “Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.” Frontiers in Psychiatry 13 (July 1, 2022). https://doi.org/10.3389/fpsyt.2022.917199.</ref> | |||
"Spielberger's State‐Trait Anxiety Inventory‐Global (STAI‐G) score" <ref>“LSD Reduces Anxiety Symptoms in Phase 2 Trial.,” ''Brown University Psychopharmacology Update'' 34, no. 1 (January 2023): 2, <nowiki>https://doi.org/10.1002/pu.30965</nowiki>.</ref> | "Spielberger's State‐Trait Anxiety Inventory‐Global (STAI‐G) score" <ref>“LSD Reduces Anxiety Symptoms in Phase 2 Trial.,” ''Brown University Psychopharmacology Update'' 34, no. 1 (January 2023): 2, <nowiki>https://doi.org/10.1002/pu.30965</nowiki>.</ref> | ||
Revision as of 14:55, 22 January 2023
Notes
Kwonmok et al. provide a list of instruments devoted to measuring Connection Outcomes.[1]
"Spielberger's State‐Trait Anxiety Inventory‐Global (STAI‐G) score" [2]
Footnotes
- ↑ Kwonmok, Ko, Knight Gemma, James J Rucker, and Anthony J Cleare. “Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.” Frontiers in Psychiatry 13 (July 1, 2022). https://doi.org/10.3389/fpsyt.2022.917199.
- ↑ “LSD Reduces Anxiety Symptoms in Phase 2 Trial.,” Brown University Psychopharmacology Update 34, no. 1 (January 2023): 2, https://doi.org/10.1002/pu.30965.
